Balyasny Asset Management »

Celldex Therapeutics shares owned by Balyasny Asset Management

Quarter-by-quarter ownership of Celldex Therapeutics (CLDX) shares owned by Balyasny Asset Management from 13F filings

Historical chart of Balyasny Asset Management investment in Celldex Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Celldex Therapeutics held by Balyasny Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Celldex Therapeutics by Balyasny Asset Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $957k 24k 39.66
2023-09-30 $755k 27k 27.52
2022-03-31 $2.1M 61k 34.06
2021-12-31 $284k 7.4k 38.58

More positions owned by Balyasny Asset Management

Ishares Tr Russell 2000 Etf (IWM)
Microsoft Corporation Call Option (MSFT)
Apple (AAPL)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
Select Sector Spdr Tr Financial (XLF)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Hess Put Option (HES)
Invesco Exchange Traded Fd T S&p500 Eql Wgt (RSP)
Amazon (AMZN)
JPMorgan Chase & Co. Call Option (JPM)
Ishares Tr Core S&p Mcp Etf (IJH)
Union Pacific Corporation Call Option (UNP)
Select Sector Spdr Tr Technology (XLK)
Boeing Company (BA)
Deere & Company (DE)

View all positions for Balyasny Asset Management

Top funds holding Celldex Therapeutics

Wellington Management Company
Eventide Asset Management
Vanguard Group
Kynam Capital Management
Point72 Asset Management
Bellevue Group
Marshall Wace
Redmile Group
Octagon Capital Advisors
Commodore Capital
Jennison Associates
Charles Schwab Investment Management
5AM Venture Management
Goldman Sachs Group
Sphera Funds Management

View all funds holding Celldex Therapeutics